[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cancer":24},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,387,0,25,[9,45,85,113,141,171,192,229,254,279,340,377,405,436,460,484,503,535,561,587,612,641,687,727,757],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100636140","a-study-on-a-predictive-model-for-efficacy-and-prognosis-of-pancreatic-carcinoma-based-on-multimodal-data-100636140",false,"NCT07561814","A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed diagnosis of pancreatic cancer.\n* Availability of preoperative and postoperative contrast-enhanced CT images at the participating center; patient records include corresponding clinical data, postoperative pathological reports, and preoperative and postoperative blood test results.\n* Underwent surgical treatment for pancreatic cancer at a participating center of this study.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years (minors).\n* Presence of other severe diseases (e.g., severe liver or kidney failure, cardiovascular or cerebrovascular diseases, malignancies other than pancreatic cancer); pregnant or breastfeeding women; individuals with mental illness;\n* patients unable to comply with follow-up or provide informed consent.\n* Presence of significant outliers (e.g., laboratory values exceeding 10 times the normal range without clinically reasonable explanation) or samples with excessive missing data.","ALL","18 Years",{"count":19,"type":20},1030,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress.\n\nThe main questions it aims to answer are:\n\n* Can combining these types of data more accurately estimate how long a person might survive?\n* Can it better predict the risk of recurrence?\n\nParticipants will not have any extra tests or treatments. They will:\n\n* Allow researchers to collect information from their existing medical records (such as surgery reports, imaging, and lab results)\n* Receive a follow-up phone call for up to 3 years to share health updates（about every 3 months for the prospective cohort）.",[24],"Pancreatic Cancer",[26,27,28,29,30,31],"Pancreatic cancer","Multimodal data","Deep learning","Predictive model","Prognosis","CT imaging","RECRUITING","2026-07-01",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2025-12-09",{"date":40,"type":20},"2029-12-31",{"name":42,"class":43},"Shanghai Zhongshan Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100597545","distance-based-exercise-to-preserve-function-and-prevent-disability-100597545","NCT07059884","Distance-Based Exercise to Preserve Function and Prevent Disability","DEFEND","Inclusion Criteria:\n\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon\u002Frectum, endometrium, esophagus, gallbladder, head\u002Fneck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed)\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder:\n\n  \\* Providing clinical care for participating patients on this study\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English\n\nExclusion Criteria:\n\n\\-",{"count":53,"type":20},104,"INTERVENTIONAL",[56],"NA","This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.",[59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,24,74,75,76],"Localized Malignant Solid Neoplasm","Anal Cancer","Bladder (Urothelial, Transitional Cell) Cancer","Breast Cancer","Cervical Cancer","Colon Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastric Cancer","Kidney Cancer","Liver Cancer","Lung Cancer","Head and Neck Cancer","Ovarian Cancer","Prostate Cancer","Rectal Cancer","Sarcoma",{"date":35,"type":36},{"date":79,"type":36},"2026-02-11",{"date":81,"type":20},"2027-08-31",{"name":83,"class":43},"Alliance for Clinical Trials in Oncology",18,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":54,"phases":94,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":112},"100573826","phase-1-a-study-of-dm002-in-patients-with-advanced-solid-tumors-100573826","NCT06751329","A Study of DM002 in Patients With Advanced Solid Tumors","A Phase I\u002FIIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\nCommon Inclusion Criteria (Part 1 and Part 2)\n\n1. Subjects must have the ability to understand and willingness to sign a written informed consent document.\n2. Subjects must be ≥18 years of age at the time of signing the informed consent form.\n3. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.\n4. Has a life expectancy of ≥3 months.\n5. Participants must meet the following laboratory values within 7 days prior to first dose of study drug:\n\n   Note: Transfusion (red blood cell or platelet) or granulocyte-colony stimulating factor (G-CSF) administration is not allowed within 2 weeks prior to laboratory assessments at Screening.\n   * Absolute neutrophil count (ANC) ≥1.5 × 10⁹\u002FL;\n   * Platelet count ≥100 × 10⁹\u002FL;\n   * Hemoglobin ≥9 g\u002FdL;\n   * Calculated creatinine clearance (CrCL) \\>60 mL\u002Fmin (Cockroft-Gault Equation);\n   * Total bilirubin ≤ 1.5 x ULN;\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 × upper limit of normal (ULN), if liver metastases are present, ≤5 × ULN;\n   * International normalized ratio (INR)\\\u003C2.0, and prothrombin time and either partial thromboplastin time (PTT) or activated PTT (aPTT) ≤1.5 × ULN, except for participants receiving anti-vitamin K derivative anticoagulant therapy who must have prothrombin time\u002FINR within therapeutic range as deemed appropriate by the Investigator.\n6. Has measurable disease based on RECIST version 1.1.\n7. Participants are required to provide tumor tissue specimens obtained within the previous 3 years for the measurement of MUC1 and\u002For HER3 and other biomarkers. For those subjects who are unable to provide tissue samples will be encouraged (but not mandatory) to undergo biopsy if the risk is manageable. If the biopsy is not possible, it should inform the sponsor for enrolment.\n\nExclusion Criteria:\n\n1. Subjects have another active invasive malignancy within 5 years, with the following exceptions and notes:\n\n   1. History of noninvasive malignancy, such as cervical cancer in situ, in situ melanoma, or ductal carcinoma in situ of the breast that is in complete remission 5 years after treatment with curative intent is allowed.\n   2. Malignancies with a negligible risk of metastasis or death (such as adequately treated basal or squamous cell skin cancer and localized prostate cancer).\n2. Current or history of a hematologic malignancy.\n3. Anticancer therapy (chemotherapy, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or other anti-cancer therapies, except for hormones for hypothyroidism or estrogen replacement therapy, anti-estrogen analogs, agonists required to suppress serum testosterone levels) within 28 days or 5 half-lives, whichever is shorter, prior to the first study dose. Radiotherapy with a wide field of radiation within 28 days, or radiotherapy with a limited field of radiation for palliation within 14 days of the first study dose. Major surgery, other than diagnostic surgery, within 4 weeks of the first study dose.\n4. Primary central nervous system (CNS) malignancies or CNS metastases. Individuals with brain metastases can be enrolled only if treated, nonprogressive brain metastases and off high-dose steroids (\\>20 mg prednisone or equivalent) for at least 4 weeks.\n5. History of known allergies to ADC, or prior discontinuation of an ADC due to treatment-related toxicities. Has received prior treatment with ADCs that include topoisomerase I (Topo I) payload, and treatment history with any investigational drug within 4 weeks before enrolment in the study.\n6. Has an uncontrolled infection requiring IV injection of antibiotics, antivirals, or antifungals.\n7. Has a pre-existing clinically significant lung diseases (e.g., interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or pre-existing ocular disorders.\n8. Clinically uncontrolled intercurrent illness, including but not limited to an ongoing active infection, active coagulopathy, uncontrolled cardiovascular disease, uncontrolled immune disease, uncontrolled diabetes, uncontrolled pleural and peritoneal effusion, psychiatric illness that would limit compliance with the study requirements and other serious medical illnesses requiring systemic therapies.\n9. Mean resting corrected QT interval corrected by Fridericia's formula (QTcF) \\>470 msec obtained from triplicate 12-lead ECGs at baseline; using concomitant medications that would prolong the QT interval.\n10. Left ventricular ejection fraction \\\u003C50% by either an echocardiogram (ECHO) or a multi-gated acquisition scan within 28 days before first dose of the study drug.\n11. Known active hepatitis B (HBV) or hepatitis C (HCV) infection. Chronic carriers of HBV infection (HBsAg-positive, undetectable HBV DNA or HBV DNA ≤2500 copies\u002Fml or 500 IU\u002Fml) receive prophylactic treatment during the study can be enrolled. Participants with a history of HCV infection have completed curative antiviral treatment and HCV viral load below the limit of quantification and HCV antibody positive but HCV ribonucleic acid (RNA) negative due to prior treatment or natural resolution should be eligible.\n12. Known human immunodeficiency virus (HIV) infection which is not well controlled. Participants should be tested for HIV prior to enrollment if required by local regulations or institutional review board (IRB)\u002Fethics committee. All the following criteria are required to define an HIV infection (positive HIV1\u002F2 antibodies test) that is well controlled: HIV viral load \\\u003C400 copies\u002FmL, CD4+ T- cell counts ≥350 cells\u002FμL, no history of acquired immunodeficiency syndrome-defining opportunistic infection within the past 12 months, and stable viral load for at least 4 weeks on same anti-HIV retroviral medications.\n13. Subjects who are from endemic areas (refer to WHO high tuberculosis burden country list, China is endemic area) will be specifically screened for tuberculosis with any available test. Subjects with active tuberculosis are excluded. Subjects who have received bacille Calmette-Guerin vaccination may have a false positive result of purified-protein derivative (PPD) test. These subjects are eligible if they have a negative result of interferon gamma release assay (IGRA).\n14. Has received a live vaccine within 30 days prior to the first dose of study drug.\n15. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia and anemia) not yet resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, ≤Grade 1 or baseline. Note: Participants may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to \\>Grade 2 for at least 3 months prior to enrolment\u002Frandomization and managed with the standard treatment) that the Investigator deems related to previous anticancer therapy, following discussion with the Sponsor's medical monitor, such as the following: Grade 2 chemotherapy-induced neuropathy, hypothyroidism, hyperglycemia.\n16. Females who are pregnant or lactating or who intend to become pregnant during participation in the study are not eligible to participate.\n17. Participants who are of reproductive potential refuse to use effective methods of birth control during participation of the study and within 7 months for female (and 4 months for male) after the last dose administration.\n18. Participants who took drugs or food which can strongly inhibit or induce the cytochrome P450 (CYP) isoenzyme, CYP3A4\u002F5 within 2 weeks prior to the first dose of DM002 or within 5 half-lives, whichever is longer.",{"count":93,"type":20},280,[95,96],"PHASE1","PHASE2","The goal of study：\n\nThe study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion.\n\nIn Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you.\n\nThe purpose of Part 1 of the study is to evaluate the safety of the study drug at different dose levels, to understand what your body does to the study drug, and to find the best dose of study drug in people who have advanced solid tumor cancers.\n\nIn Part 2, participants will receive the best dose level that was determined in Part 1 of the study.\n\nThe purpose of Part 2 of the study is to evaluate the safety of the study drug at the dose level determined in Part 1, to understand what your body does to the study drug, and to see how your cancer responds to the study drug.\n\nParticipants will:\n\nParticipants will have 17 or more visits to the study centre. This study has a screening phase of up to 28 days , and a treatment phase with cycles of 21 days each. Participants will also have an End of Treatment (EOT) visit 21 days after the final study drug treatment, and a Follow-up visit 30 days after the EOT visit . Participants will be contacted by telephone every 3 months after the Follow-up visit to check on the wellbeing and record any new anticancer therapy they may have started.",[99,100,101,102,103,24],"Ovarian Neoplasms","Prostatic Neoplasms","Endometrial Neoplasms","Colorectal Neoplasms","Solid Carcinoma",{"date":35,"type":36},{"date":106,"type":36},"2025-02-17",{"date":108,"type":20},"2028-04-18",{"name":110,"class":111},"Xadcera Biopharmaceutical (Suzhou) Co., Ltd.","INDUSTRY",5,{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":54,"phases":123,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":44},"100643558","early-phase-1-glp-1-ra-plus-soc-treatment-in-first-line-metastatic-pancreatic-colorectal-or-hepatocellular-cancer-100643558","NCT07627191","GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer","GLP-1 Receptor Agonist Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer","Inclusion Criteria:\n\n* Histological or cytological diagnosis of pancreatic adenocarcinoma or colorectal adenocarcinoma. Previous tumor tissue testing is acceptable. Please refer to the \"additional HCC cohort criteria\" below.\n* The subject has disease that is not amenable to curative-intent management (e.g., oligometastatic disease)\n* Measurable disease per RECIST v1.1 as determined by the investigator\n* Patients must be appropriate candidates for first-line, SOC treatment.\n\n  * SOC treatment as defined by NCCN® guidelines or institutional standard is allowable, however, options restricted to:\n\n    * Colorectal: FOLFOX or FOLIFIRI +\u002F- bevacizumab\n    * Pancreatic: mFOLFIRINOX\n    * HCC: Tremelimumab\u002FDurvalumab\n  * Patients are eligible who received prior perioperative chemotherapy for curative intent treatment and recurred ≥ 6 months since last dose of chemotherapy.\n* ≥ 18 years old on day of consent\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate archival frozen or fixed tissue available from primary or metastatic site for genotypic analysis (at least 15 unstained slides and\u002For tumor block)\n* Adequate hematologic and organ function laboratory values as follows:\n\n  * The ANC ≥ 1500\u002Fmm3 without colony stimulating factor support;\n  * Platelets ≥ 75,000\u002Fmm3;\n  * Hemoglobin ≥ 9 g\u002FdL;\n  * Bilirubin ≤ 1.5 ´ the ULN. For subjects with known Gilbert's disease, bilirubin ≤ 3.0 mg\u002FdL;\n  * Serum albumin ≥ 2.8 g\u002Fdl;\n  * ALT and AST ≤ 3.0 ´ ULN;\n  * Serum creatinine ≤ 1.5 ´ ULN or creatinine clearance (CrCl) ≥ 40 mL\u002Fmin. For creatinine clearance estimation, the Cockcroft and Gault equation should be used:\n\n    * Male: CrCl (mL\u002Fmin) = (140 - age) × wt (kg) \u002F (serum creatinine × 72);\n    * Female: Multiply above result by 0.85;\n* The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document\n* Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control or practice abstinence during the study and for 4 months after the last dose of study drug(s);\n\nAdditional Inclusion Criteria for HCC Cohort ONLY:\n\n* Histologically or radiologically confirmed hepatocellular carcinoma (per AASLD\u002FEASL criteria)\n* Unresectable or advanced HCC not amenable to curative surgery or locoregional therapy.\n* Barcelona Clinic Liver Cancer (BCLC) stage B or C.\n* Child-Pugh Score Class A; or Child-Pugh Class B7 or B8 at discretion of treating physician\n* Patients with HBV infection, characterized by positive hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibodies (anti-HBcAb) with detectable HBV deoxyribonucleic acid (DNA) (≥10 IU\u002FmL or above the limit of detection per local or central lab standard), must be treated with antiviral therapy, as per institutional practice to ensure adequate viral suppression (HBV DNA \\\u003C2000 IU\u002FmL) before enrolment. Patients must remain on antiviral therapy for the duration of their participation in the EAP and for 6 months after the last dose of EAP medication. Patients who test positive for anti-hepatitis B core (HBc) with undetectable HBV DNA (\\\u003C10 IU\u002FmL or under the limit of detection per local or central lab standard) do not require anti-viral therapy before enrolment. These participants will be tested at every cycle to monitor HBV DNA levels and initiate anti-viral therapy if HBV DNA is detected (≥10 IU\u002FmL or above the limit of detection per local or central lab standard). HBV DNA detectable patients must initiate and remain on anti-viral therapy for time they are on the EAP and for 6 months after the last dose of EAP medication.\n\n  o Note: Testing required for subjects with a known history otherwise not required.\n* Patients with HCV infection must have confirmed diagnosis of HCV characterized by the presence of detectable HCV ribonucleic acid (RNA) or anti-HCV antibody upon enrolment (management of this disease is per local institutional practice).\n\nExclusion Criteria\n\n* The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) for metastatic and\u002For unresectable disease.\n* BMI \\\u003C 25 kg\u002Fm2\n* For colorectal cancer only - Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) tumors.\n* For colorectal cancer only - BRAF V600E mutant tumors.\n* A personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).\n* A prior hypersensitivity reaction to semaglutide or any of the excipients in WEGOVY®. Serious hypersensitivity reaction, including anaphylaxis and angioedema, have been reported with WEGOVY®.\n* Cachexia\n* Subjects on insulin.\n* Subjects with a history of diabetic retinopathy\n* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before the first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatment\n* The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n  o Cardiovascular disorders including:\n  * For patients being considered for bevacizumab (or bevacizumab biosimilar) only:\n* Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) \\> 150 mm Hg systolic or \\> 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment;\n* thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (eg, vena cava filter) within 6 months before the first dose of study treatment.\n\n  * Any of the following within 6 months before the first dose of study treatment:\n* unstable angina pectoris;\n* clinically-significant cardiac arrhythmias;\n* stroke (including transient ischemic attack (TIA), or other ischemic event);\n* myocardial infarction;\n\n  * GI disorders particularly those associated with a high risk of perforation or fistula formation including:\n\n    * Unresolved abdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess.\n    * Uncontrolled nausea, vomiting, or abdominal pain.\n  * Other clinically significant disorders that would preclude safe study participation\n* Major surgery within 8 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.\n* Females who are known or suspected to be pregnant or lactating. Women of childbearing potential must have a negative serum pregnancy test result within screening.\n* Female patients planning on becoming pregnant while on study.\n* Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment.\n* Male subjects unwilling to abstain from donating sperm during treatment.\n* Inability to comply with self-administration of GLP-1 RA subcutaneous injections.\n* Subject has known sensitivity to any of the products or components to be administered during dosing.\n* Concurrent use of other semaglutide containing products or any other GLP-1 receptor agonist.\n* Diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.\n* Subject likely to not be available to complete all protocol-required study visits or procedures and\u002For to comply with all required study procedures to the best of the subject and investigator's knowledge.\n* History or evidence of any other clinically significant disorder, condition or disease that in the opinion of the investigator, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.\n\nAdditional Exclusion Criteria for HCC Cohort ONLY:\n\n* Child-Pugh Score Class B9; or Child-Pugh Class C\n* Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 28 days of the first dose of EAP treatments.\n* History of allogenic organ transplantation (e.g., liver transplant).\n* History of hepatic encephalopathy within the past 12 months or requirement for medications to prevent or control encephalopathy (e.g., no lactulose, rifaximin, etc if used for purposes of hepatic encephalopathy.\n* Clinically meaningful ascites, defined as any ascites requiring non-pharmacologic intervention (e.g., paracentesis) to maintain symptomatic control, within 2 months before the first EAP treatment dose. Patients on stable doses of diuretics for ascites for ≥2 months are eligible.\n* Patients with main portal vein thrombosis (i.e., thrombosis in the main trunk of the portal vein, with or without blood flow) on baseline imaging.\n* Active or previously documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[except for diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). Patients without active disease in the last 5 years are excluded unless discussed with the Treating Physician and considered appropriate for EAP participation. The following are exceptions to this criterion:\n\n  * Patients with vitiligo or alopecia\n  * Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement\n  * Any chronic skin condition that does not require systemic therapy\n  * Patients with celiac disease controlled by diet alone\n* Patients co-infected with HBV and HCV, or co-infected with HBV and hepatitis D virus (HDV). HBV positive (presence of HbsAg and\u002For anti-HBcAb with detectable HBV DNA); HCV positive (presence of anti-HCV antibodies); HDV positive (presence of anti-HDV antibodies).\n\n  o Note: Testing required for subjects with a known history otherwise not required.\n* Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.\n* History of active primary immunodeficiency.\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of EAP treatment. The following are exceptions to this criterion:\n\n  * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection)\n  * Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or its equivalent\n  * Steroids as pre-medication for hypersensitivity reactions (e.g., CT scan pre-medication)\n* Receipt of live attenuated vaccine within 30 days before first dose of treatment. Note: patients, if enrolled, should not receive live vaccine while receiving study treatment, and up to 30 days after the last dose of study treatment.\n* Previous randomization or treatment in a previous durvalumab and\u002For tremelimumab clinical study regardless of treatment arm assignment.\n* Patients who have received anti-PD-1, anti-PD-L1, or anti-CTLA-4 before the first dose of EAP treatment.","99 Years",{"count":122,"type":20},30,[124],"EARLY_PHASE1","There is a growing number of patients diagnosed with gastrointestinal cancers who are also simultaneously being treated with GLP-1 Receptor Agonists (RA)s. To date, no clinical trial data exists to establish safety and\u002For feasibility with use of GLP-1 RAs during chemotherapy in the metastatic setting. The goal of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and correlative analyses of combining GLP-1 RAs with standard chemotherapy in patients with metastatic pancreatic, colorectal, or hepatocellular cancers in the first-line setting.",[24,127,128],"Colorectal Cancer","Hepatocellular Carcinoma",[130,131],"GLP1 receptor agonists","gastrointestinal cancer","NOT_YET_RECRUITING","2026-06-30",{"date":35,"type":36},{"date":136,"type":20},"2026-07-10",{"date":138,"type":20},"2028-06-30",{"name":140,"class":43},"University of Arizona",{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":148,"sex":16,"minAge":149,"maxAge":4,"enrollmentInfo":150,"targetDuration":152,"studyType":21,"phases":4,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":170},"100607264","exopert-emerald-clinical-study-100607264","NCT07186296","EXoPERT EMERALD Clinical Study","EXoPERT EMERALD: Early Multi-cancer Study of EV's Ramen-AL Linked Diagnosis Clinical Study Protocol","Inclusion Criteria:\n\n* Subject aged 45 years or older with a biopsy-proven or clinically suspected primary lung, breast, colorectal, pancreatic, or ovarian cancer, based on objective findings such as radiological, serological, endoscopic, or cytological findings, whose blood was collected prior to any systemic or definitive therapy for the cancer.\n* Subjects who are willing and able to provide written informed consent.\n* Subjects who are willing and able to comply with the study requirements.\n\nExclusion Criteria:\n\n* Any history of cancer diagnosed and treated within 5 years prior to the date of consent.\n* Subjects with a history of previous cancer treatment via surgical resection, hormonal cancer treatment, chemotherapy, radiotherapy within the past 6 months for recent cancer diagnosis.\n* Subjects who have any history of an allogeneic bone marrow, stem cell transplant, or solid organ transplant.\n* Subjects who are pregnant or breastfeeding women.\n* Subjects who have consented and have undergone treatment in any other cancer related clinical trials withinthe past 6 months.\n* Subjects who are currently in active treatment for drug abuse.\n* Subjects who have received any treatment related to lung, breast, colorectal, pancreatic, or ovarian nodules, such as hormones prior to entering the study.\n* Unsuitable sample for testing due to contamination, hemolysis, etc.",true,"45 Years",{"count":151,"type":20},1400,"1 Day","The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhanced Raman spectroscopy (SERS) profiles of extracellular vesicles (EVs) extracted from human plasma for the early detection of multiple cancers, including lung, ovarian, breast, pancreatic, and colorectal cancers.",[62,64,24,73,71],[156,157,158,159,160,161],"Early-stage","In vitro Diagnostic Test","Artificial intelligence","extracellular vesicles","multi cancer diagnosis","cancer","2026-06-28",{"date":33,"type":36},{"date":165,"type":36},"2025-05-09",{"date":167,"type":20},"2026-08-31",{"name":169,"class":111},"EXoPERT",9,{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":54,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100620630","total-pancreatectomy-with-islet-autotransplantation-tpiat-for-high-risk-patients-with-pancreatic-tumors-100620630","NCT07360119","Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors","Total Pancreatectomy With Islet Autotransplantation (TPIAT) for Patients With Periampullary Neoplasms at High Risk for Pancreaticojejunostomy Leakage After Pancreaticoduodenectomy: a Single-center, Prospective, Single-Arm, Observational Study","Inclusion Criteria:\n\n* Adults aged 18 and older.\n* Patients with periampullary neoplasms requiring pancreaticoduodenectomy, including but not limited to:\n* Distal bile duct adenocarcinoma\n* Duodenal adenocarcinoma\n* Leiomyosarcoma of the duodenum\n* Pancreatic neuroendocrine neoplasms\n* Ampullary adenoma\n* Duodenal gastrointestinal stromal tumor (GIST)\n* High-risk Intraductal Papillary Mucinous Neoplasm (IPMN) as per Fukuoka criteria\n* Mucinous cystic neoplasm\n* Serous cystadenoma\n* Presence of soft pancreatic tissue and a main pancreatic duct ≤ 2 mm based on preoperative imaging.\n* Adequate islet function with measurable C-peptide preoperatively to justify islet isolation and transplant.\n\nExclusion Criteria:\n\n* Pregnancy\n* Active alcohol or illicit drug use\n* Poorly controlled psychiatric illness that limits compliance with care\n* Pre-existing insulin-dependent diabetes with absent C-peptide\n* Portal vein thrombosis or significant portal hypertension\n* Contraindications to major surgery\n* Body Mass Index (BMI) \\> 35 kg\u002Fm².",{"count":122,"type":20},[56],"This is a single-center, prospective, single-arm study evaluating the safety and feasibility of total pancreatectomy with islet autotransplantation (TPIAT) in carefully selected adult patients with periampullary neoplasms who are considered at high risk for postoperative pancreatic fistula after pancreaticoduodenectomy. Eligible patients will undergo open or robotic TPIAT as part of the patient's surgical management. Perioperative outcomes, postoperative complications, metabolic outcomes, and early oncologic outcomes will be collected prospectively as part of routine clinical care and analyzed to assess the safety and feasibility of this approach.",[182,24],"Periampullary Neoplasms","2026-06-26",{"date":185,"type":36},"2026-06-29",{"date":187,"type":20},"2026-08-01",{"date":189,"type":20},"2031-02-01",{"name":191,"class":43},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":228},"100602476","destiny-pantumour04-100602476","NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","130 Years",{"count":202,"type":20},100,"This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[205,60,206,63,65,66,67,207,72,70,208,209,210,211,73,24,74,212,213,76,214,215,216,217,218,219,220],"Adenocarcinoma (NOS)","Bladder Cancer","Gastrointestinal Stromal Tumour","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer",{"date":185,"type":36},{"date":223,"type":36},"2025-09-18",{"date":225,"type":20},"2028-03-30",{"name":227,"class":111},"AstraZeneca",17,{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":148,"sex":16,"minAge":235,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":54,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":44},"100440278","phase-1-mutant-kras--targeted-long-peptide-vaccine-for-patients-at-high-risk-of-developing-pancreatic-cancer-100440278","NCT05013216","Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer","Inclusion Criteria:\n\nCohort A: Must fall into one of the three categories defined as high risk of developing pancreatic cancer and are undergoing pancreatic surveillance AND 2) have documented radiographic evidence of a pancreatic abnormality such as a pancreatic cyst.\n\n* High Risk Group 1 (familial pancreatic cancer relatives):\n\n  * \\>\u002F=55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and\n  * Come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and\n  * Have a first-degree relationship with at least one of the relatives with pancreatic cancer.\n  * If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened.\n* High Risk Group 2 (Germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of \\~10% or higher):\n\n  * \\>\u002F=40 years old and the Patient is a carrier of FAMMM (p16\u002FCDKN2A) mutation regardless of family pancreas cancer history.\n\nOR\n\n* \\>\u002F= 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and the Patient is a carrier of a known BRCA2, ATM, PALB2 mutation.\n* Persons with known genetic mutation should have proof of mutation status. Those who had research-related genetic testing must have confirmation by a clinical CLIA-certified laboratory.\n\n  o High Risk Group 3 (Germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of \\~5%):\n* \\>\u002F= 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and\n* The patient is a carrier of a known, BRCA1, or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is \\> 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened.\n* Persons with known genetic mutation should have proof of mutation status. Those who had research-related genetic testing must have confirmation by a clinical CLIA-certified laboratory.\n* Cohort A: Patients must have a pancreatic imaging abnormality that is being followed by pancreatic imaging surveillance (EUS and\u002For MRI and \u002For CT), such as a pancreatic cyst consistent with an IPMN or parenchymal abnormalities consistent with PanIN.\n\n  * Cohort B: Patients must have clinical, radiographic, or histologic evidence of pancreatic cystic neoplasm with high-risk features warranting surgical resection per the discretion of the treating hepatobiliary surgeon.\n  * Cohort B: Patients must have cystic fluid testing that demonstrates the presence of one of the six KRAS mutations included in the study vaccine.\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.\n* Ability to understand and willingness to sign a written informed consent document.\n* Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.\n* Men must use acceptable form of birth control while on study.\n\nExclusion Criteria:\n\n* If expected to require any other form of systemic or localized antineoplastic therapy while on study.\n* Within 4 weeks prior to first dose of study drug.\n\n  o Any systemic or topical corticosteroids at immunosuppressive agents.\n* Within 4 weeks prior to first dose of study drug.\n\n  * Any investigational device.\n  * Has received a live vaccine.\n  * Received any allergen hyposensitization therapy.\n  * Any major surgery.\n* Infection with HIV or hepatitis B or C.\n* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements monoclonal antibody.\n* Has a diagnosis of immunodeficiency.\n* Any other sound medical, psychiatric, and\u002For social reason as determined by the Investigator.\n* Unwilling or unable to follow the study schedule for any reason.\n* Are pregnant or breastfeeding.","40 Years",{"count":237,"type":20},37,[95],"This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant for patients who have been identified to be at risk of developing pancreatic cancer.",[241,24],"High Risk Cancer",[243,244,245,246,247],"KRAS Peptide Vaccine","Neoantigen Vaccines","Cancer Vaccines","Immunotherapy","Pancreatic Ductal Adenocarcinoma (PDAC)",{"date":133,"type":36},{"date":250,"type":36},"2022-04-11",{"date":252,"type":20},"2031-05-01",{"name":191,"class":43},{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":263,"studyType":21,"phases":4,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":44},"100644523","spatial-multi-omics-and-intelligent-early-warning-of-pancreatic-cancer-cachexia-100644523","NCT07670286","Spatial Multi-omics and Intelligent Early Warning of Pancreatic Cancer Cachexia","Spatial Multi-omics Mechanism Analysis and Multimodal Intelligent Early Warning of Cachexia in Pancreatic Cancer","Inclusion Criteria:\n\n* Patients with pathologically confirmed pancreatic ductal adenocarcinoma.\n* Aged ≥18 years with an expected survival time of ≥1 month (to be assessed for the advanced cohort). Assessment criteria: Comprehensive evaluation based on the patient's radiological tumor burden, vital organ function and physical status. Specific quantitative indicators: Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2, or Karnofsky Performance Status (KPS) score of ≥60. For patients in the advanced cohort, the assessment shall be jointly confirmed by two attending physicians with the professional title of associate chief physician or above in combination with radiological examination results.\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Complicated with other untreated malignant tumors or severe mental disorders.\n* Pregnant women or patients unable to cooperate with follow-up.",{"count":262,"type":20},500,"1 Year","The goal of this observational study is to explore the spatial multi-omics mechanism of cachexia in pancreatic cancer and construct a high-precision multimodal intelligent early warning model for its early diagnosis in pathologically confirmed pancreatic ductal adenocarcinoma patients aged ≥18 years with an expected survival of ≥1 month.\n\nThe main questions it aims to answer are: 1) Can spatial transcriptomics\u002Fmetabolomics reveal the interaction mechanism between tumor microenvironment and metabolism in pancreatic cancer cachexia? 2)Can a multimodal AI early warning model be built to achieve accurate early identification of pancreatic cancer cachexia? Researchers will compare the surgical cohort and advanced cohort to see the differences in cachexia incidence and progression rules among different subgroups. Participants will complete baseline questionnaires on physical and mental state, nutrition and muscle strength, undergo imaging examinations and provide biological samples (blood, feces, tissue etc.), and receive regular follow-ups for updated questionnaires, imaging rechecks and supplementary biological sample collection until death, loss to follow-up or voluntary withdrawal.",[24,266],"Cachexia; Cancer; Sarcopenia",[268,269,24,270],"Spatial Multi-omics","Multimodal intelligent","Cachexia","2026-06-25",{"date":183,"type":36},{"date":274,"type":36},"2026-04-24",{"date":276,"type":20},"2028-08-31",{"name":278,"class":43},"Peking Union Medical College Hospital",{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":148,"sex":16,"minAge":286,"maxAge":287,"enrollmentInfo":288,"targetDuration":290,"studyType":21,"phases":4,"briefSummary":291,"conditions":292,"keywords":322,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":339},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals","19 Years","110 Years",{"count":289,"type":20},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[24,217,71,66,293,64,75,294,60,295,296,297,68,70,298,299,300,301,206,69,302,74,215,303,218,304,305,306,307,308,309,310,311,213,312,313,314,315,62,316,208,76,317,318,73,65,219,319,320,321],"Thymus Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Penile Cancer","Ureter Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Leukemia","Unknown Primary Tumor","Multiple Myeloma","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[24,217,323,324,325,326,327,328,329,330,62,331,320,321],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor",{"date":185,"type":36},{"date":334,"type":36},"2013-11-01",{"date":336,"type":20},"2099-12",{"name":338,"class":43},"University of Nebraska",42,{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":54,"phases":350,"briefSummary":352,"conditions":353,"keywords":360,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":376},"100630728","phase-3-study-of-daraxonrasib-and-daraxonrasib--gnp-as-first-line-treatment-in-patients-with-metastatic-pancreatic-adenocarcinoma-100630728","NCT07491445","Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma","RASolute 303","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically or cytologically confirmed pancreatic adenocarcinoma.\n* Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent.\n* Documented RAS mutation status, either mutant or wild-type.\n* Measurable disease per RECIST v1.1.\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Prior treatment with systemic anticancer therapy in metastatic setting or prior RAS-targeted therapy in any treatment setting.\n* Active or known history of untreated central nervous system metastatic disease.\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 28 days prior to randomization.\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.",{"count":349,"type":20},900,[351],"PHASE3","The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.",[24,354,355,356,247,357,358,359],"Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Adenocarcinoma Metastatic","Pancreatic Adenocarcinoma","Pancreatic Adenosquamous Carcinoma",[24,355,361,362,363,364,365,366,367,354,357,359,358],"Pancreatic Ductal Adenocarcinoma","RAS","KRAS","NRAS","HRAS","RAS Wild-Type","RAS Mutation","2026-06-24",{"date":271,"type":36},{"date":371,"type":36},"2026-03-09",{"date":373,"type":20},"2029-03",{"name":375,"class":111},"Revolution Medicines, Inc.",13,{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":54,"phases":386,"briefSummary":387,"conditions":388,"keywords":391,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":404},"100624410","phase-3-a-study-to-evaluate-the-effectiveness-and-safety-of-setidegrasib-given-with-either-mfolfirinox-or-nalirifox-chemotherapies-in-people-with-pancreatic-cancer-100624410","NCT07409272","A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Participant has histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC) with documented Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutation based on local or central testing (confirmation of a participant's positive KRAS G12D mutation result must be available prior to randomization).\n* Participant has no option for surgical resection or radiotherapy with curative intent.\n* Participant consents to and provides a baseline tumor tissue specimen for the study during screening. The sample must meet the requirements described in the laboratory manual and the tumor sample guidance.\n* Participant has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 within 7 days prior to randomization.\n* Participant has adequate organ function as indicated by the following laboratory values within 7 days prior to randomization (if a participant has received a recent blood transfusion, the latest laboratory tests must be obtained ≥ 14 days after any blood transfusion). The laboratory values prior to the initiation of the first dose of setidegrasib\u002Fplacebo (or mFOLFIRINOX\u002FNALIRIFOX, if chemotherapy is administered during the screening period) should be used to determine eligibility. Participants who receive mFOLFIRINOX\u002FNALIRIFOX during the screening period must meet these criteria within 7 days prior to the start of on-treatment chemotherapy (i.e., C1D1).\n* Participant agrees not to participate in another interventional study while receiving study intervention in the present study (participant who is currently in the follow-up period of an interventional clinical trial is allowed).\n\nExclusion Criteria:\n\n* Participant has neuroendocrine, acinar pancreatic carcinoma or pancreatic cancer with squamous\u002Fadenosquamous features.\n* Participant has another prior malignancy active (i.e., requiring treatment, including hormonal therapies, or intervention) within the previous 2 years different from the primary malignancy for this study, except for local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, which are allowed.\n* Participant has chronic inflammatory bowel disease, bowel obstruction and\u002For severe uncontrolled diarrhea.\n* Participant has peripheral sensory neuropathy with functional impairment.\n* Participant has ascites and\u002For pleural effusion that require invasive interventions within 30 days prior to randomization or have an indwelling drainage catheter.\n* Participant has symptomatic pulmonary embolism or pulmonary embolism not being treated with anticoagulation.\n* Participant has a history of interstitial lung disease or pulmonary fibrosis.\n* Participant has uncontrolled seizure disorder or refractory to antiepileptics.\n* Participant has known homozygous uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.\n* Participant has had a myocardial infarction, unstable angina or coronary artery bypass surgery within 6 months prior to randomization or currently has an uncontrolled illness including but not limited to symptomatic congestive heart failure, clinically significant cardiac disease (e.g., cardiomyopathy, infiltrative cardiac disease, etc.), unstable angina pectoris, cardiac arrhythmia, obligate use of a cardiac pacemaker or long QT interval (QT) syndrome.\n* Participant has received any prior systemic therapy for their metastatic PDAC (except with up to 2 doses \\[i.e., 28 days; 1 cycle\\] of mFOLFIRINOX or NALIRIFOX during the screening period. If a participant received \\[neo\\]adjuvant chemotherapy, tumor recurrence or disease progression must have occurred ≥ 6 months after completing the last dose of the \\[neo\\]adjuvant therapy).\n* Participant has had prior treatment with a KRAS G12D-targeted agent.\n* Participant has a corrected QT interval by Fridericia (QTcF) (single electrocardiogram \\[ECG\\]) \\> 470 msec during the screening period.",{"count":385,"type":20},614,[351],"Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic cancer. The first treatment that people usually receive is chemotherapy. At the time this study started, some of the main standard chemotherapies for pancreatic cancer were mFOLFIRINOX or NALIRIFOX.\n\nGenes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Many people with pancreatic cancer have a faulty KRAS gene. One such change in the KRAS gene is called a G12D mutation. Researchers are looking for ways to stop the actions of abnormal proteins made from the KRAS G12D mutation.\n\nThis study is about setidegrasib given with chemotherapy in people with pancreatic cancer who have the KRAS G12D mutation. Before setidegrasib can become an approved treatment, clinical studies need to be completed to understand how it works and how safe it is.\n\nThe main aim is to learn if people who are given setidegrasib with chemotherapy live for longer than people who are given placebo with chemotherapy. Other aims are to learn if setidegrasib delays the cancer and symptoms returning, how the body processes setidegrasib, and its safety, when given with chemotherapy.\n\nPeople in this study will be adults with metastatic pancreatic cancer with the G12D mutation in their KRAS gene. Surgery or radiotherapy will not be an option to cure their cancer.\n\nPeople cannot take part if the cancer cells have spread to the thin tissue covering the brain and spinal cord (leptomeningeal disease), have symptoms of cancer in the brain or nervous system, or have recently had some other cancers that required treatment.\n\nIn this study, people are given either setidegrasib with mFOLFIRINOX or NALIRIFOX chemotherapy, or a placebo with mFOLFIRINOX or NALIRIFOX chemotherapy. Whether people receive setidegrasib or placebo is decided by chance. The study doctor decides which chemotherapy (mFOLFIRINOX or NALIRIFOX) people receive. People will only receive NALIRIFOX chemotherapy (with setidegrasib or placebo) after the safety of setidegrasib with NALIRIFOX chemotherapy has been confirmed in another ongoing setidegrasib study. All of the study treatments are given slowly through a tube into a vein (infusion). People will continue to receive study treatment until their cancer gets worse, they can't tolerate the study treatment, they start other cancer treatment, they or the doctor decides the person should stop receiving study treatment, or sadly they pass away. There will be safety checks at each visit, and the doctors will continue to check for medical problems and people's wellbeing throughout the study.",[24,389,390],"Metastatic Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma",[24,389,390,392,393,394,355,395,396],"ASP3082","setidegrasib","KRAS G12D","mFOLFIRINOX","NALIRIFOX",{"date":271,"type":36},{"date":399,"type":36},"2026-02-17",{"date":401,"type":20},"2029-08-31",{"name":403,"class":111},"Astellas Pharma Global Development, Inc.",34,{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":148,"sex":16,"minAge":413,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":54,"phases":416,"briefSummary":417,"conditions":418,"keywords":420,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":435},"100637784","pancreatic-cancer-screening-using-the-enzeavour-assay-in-japan-100637784","NCT07605819","Pancreatic Cancer Screening Using the Enzeavour Assay in Japan","Pancreatic Cancer Screening Using Single-Molecule Enzyme Activity-Based Liquid Biopsy, Enzeavour: A Single-Arm Interventional Feasibility Study Protocol in Japan","ENZEAVOUR FS","Inclusion Criteria:\n\n* Asymptomatic adults attending participating facilities for routine health checkups, organized cancer screening, or both\n* Able to understand the study procedures and provide written informed consent before enrollment\n\nExclusion Criteria:\n\n* Documented clinical history of pancreatic cancer\n* Considered unable or unwilling to undergo any required diagnostic imaging modality (MRCP, EUS, or contrast-enhanced CT) after a positive index test result\n* Any medical, psychological, or social condition that, in the opinion of the principal investigator at each participating site, makes participation inappropriate or compromises study integrity","20 Years",{"count":415,"type":20},10000,[56],"This nationwide, multicenter, prospective, single-arm interventional feasibility study evaluates the Enzeavour Pancreatic Cancer assay in routine health checkups and cancer screening in Japan. Approximately 10,000 asymptomatic adults will be enrolled. Participants with an Enzeavour Score above 0.369 will undergo diagnostic work-up as clinically indicated. The primary outcome is pancreatic cancer detection rate within 12 months after the index blood draw, and the secondary outcome is positive predictive value.",[24,419],"Pancreatic Neoplasms",[421,422,423,424,425,426],"pancreatic cancer screening","liquid biopsy","blood-based biomarker","early detection","Enzeavour","single-molecule enzyme activity","2026-06-23",{"date":183,"type":36},{"date":430,"type":36},"2026-02-04",{"date":432,"type":20},"2028-12-31",{"name":434,"class":111},"Cosomil, Inc.",48,{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":54,"phases":445,"briefSummary":446,"conditions":447,"keywords":448,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":455,"leadSponsor":457,"locationsCount":459},"100644506","phase-1-a-study-of-eli-002-7p-with-or-without-tislelizumab-in-people-with-pancreatic-cancer-100644506","NCT07671339","A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer","A Pilot Study of Neoadjuvant mFOLFIRINOX and ELI002-7P Treatment With or Without Tislelizumab in Borderline and Resectable Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n\\- Documentation of Disease\n\n* Pathologically confirmed adenocarcinoma of the pancreas.\n* Presence of one of seven KRAS mutations: G12D, G12V, G12R, G12C, G12A, G12S, or G13D.\n\n  * Definition of Disease\n* Patients must have resectable or borderline resectable localized disease as defined by NCCN Guidelines v2.2025. Staging CT or MRI of the chest\u002Fabdomen\u002Fpelvis at enrollment must be negative for metastatic disease.\n\n  * Prior Treatment\n* Up to 4 doses of neoadjuvant mFOLFIRINOX are allowed prior to enrollment. Resolution of all toxicities of prior therapy or surgical procedures to baseline or Grade\n\n  1 (except for hypothyroidism requiring medication, which must have resolved to Grade ≤2), alopecia, and other toxicities considered clinically nonsignificant and\u002For stable on supportive therapy as determined by the investigator).\n  * Age ≥18 years.\n  * ECOG Performance Status 0-1\n  * Pregnancy and Nursing\n* Not pregnant or breastfeeding.\n* Evidence of post-menopausal status or a negative urinary or serum pregnancy test for females of child-bearing potential within 28 days prior to initiation of treatment.\n\n  * Required Organ Function\n  * Hematologic function:\n* ANC ≥1,500\u002Fmm³\n* Platelets ≥100,000\u002Fmm³\n* Hemoglobin ≥8.0 g\u002FdL\n\n  * Renal function:\n* Creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault formula or 24-hour urine collection).\n\n  * Hepatic function:\n* Total bilirubin ≤1.5 × ULN (Gilbert's syndrome allowed up to ≤3 × ULN)\n* AST and ALT ≤3 × ULN Albumin: ≥2.5 g\u002FdL\n\n  * Cardiac function: Patients with known cardiac disease or prior exposure to cardiotoxic agents should undergo risk assessment per NYHA classification; patients must be class or better. Compliance and Life Expectancy\n  * Patient is willing and able to comply with protocol procedures, treatment, and follow-up.\n* Estimated life expectancy of at least 12 weeks per treating physician.\n\n  * Comorbid Conditions\n* No active infection requiring parenteral antibiot ic(s)\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n\n  * Allergies: No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent (s) (or any of its excipients).\n  * Concomitant Medications\n* Concomitant medication use should only exclude patients when clinically relevant drug-drug interactions or overlapping toxicities are expected to impact safety or efficacy. All concomitant medications from 7 days prior to screening through 12 weeks after the last dose of investigational product must be documented in the medical record.\n\n  * Contraception Requirements\n* Patients of reproductive potential must use highly effective contraception from screening through 90 days after the last dose of immunotherapy.\n\nExclusion Criteria:\n\n* Locally advanced unresectable PDAC (per NCCN v2.2025), including unreconstructable venous anatomy, arterial tumor contact ≥180° (superior mesenteric, celiac, or hepatic artery), or aortic invasion\n* Metastatic PDAC.\n* Prior treatment with TNF receptor agonists (OX40, CD27, CD137\u002F4-1BB, GITR) or prior checkpoint inhibitor therapy (anti-CTLA-4, anti-PD-1, anti-PD-L1).\n* Active infection including tuberculosis, hepatitis A, active HBV (HBsAg+), or active HCV. Patients with resolved HBV (anti-HBc+, HBsAg-) may enroll. HCV Ab+ patients are eligible if HCV RNA PCR is negative. Successfully treated cholangitis is not exclusionary if no active infection remains.\n* Known HIV infection not meeting the on-study guideline criteria above.\n* Active or prior documented autoimmune\u002Finflammatory disorders including: IBD, systemic lupus erythematosus, sarcoidosis, granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, systemic sclerosis, CNS or motor neuropathy of autoimmune origin (e.g., Guillain-Barré, myasthenia gravis, multiple sclerosis). Exceptions: vitiligo, alopecia, stable hypothyroidism on replacement, remote (\\>5 years) inactive autoimmune disease, or celiac disease controlled by diet.\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic CHF, unstable angina, uncontrolled arrhythmia, uncontrolled hypertension, interstitial lung disease, serious GI conditions with chronic diarrhea, or psychiatric\u002Fsocial situations limiting compliance.\n* Current or prior systemic immunosuppressive medication within 14 days of first ELI-002 7P dose.\n* Exceptions: intranasal\u002Finhaled\u002Ftopical steroids, local steroid injections, physiologic replacement doses (≤10 mg prednisone\u002Fday or equivalent), steroids as premedication for imaging contrast allergy, or limited steroid use as anti-emetic with mFOLFIRINOX.\n* Receipt of a live attenuated vaccine within 30 days prior to first dose of immunotherapy.\n* Pregnancy, breastfeeding, or unwillingness to use effective contraception during treatment and for 90 days after last immunotherapy dose.\n* Allergy or hypersensitivity to study drugs or excipients.\n* Any other malignancy within 3 years except adequately treated cervical carcinoma in situ, non-muscle-invasive bladder cancer, localized prostate cancer, or non-melanoma skin cancers.\n* Prior allogeneic organ transplantation.",{"count":444,"type":20},20,[95],"The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a KRAS mutation. In addition, the researchers are doing this study to find out whether the study treatment is effective against PDAC.",[24],[449,450,451],"ELI-002 7P","Tislelizumab","25-386","2026-06-22",{"date":183,"type":36},{"date":452,"type":36},{"date":456,"type":20},"2028-06",{"name":458,"class":43},"Memorial Sloan Kettering Cancer Center",7,{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":54,"phases":468,"briefSummary":469,"conditions":470,"keywords":471,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":44},"100531903","phase-1-intra-tumoral-mitazalimab-cd40-antibody-with-irreversible-electroporation-ire-in-locally-advanced-pancreas-cancer-100531903","NCT06205849","Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer","Phase 1 Clinical Trial of Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Histologically\u002Fcytologically-confirmed pancreatic ductal adenocarcinoma (PDAC)\n* Persons, aged \\> 18 years of age, as PDAC is extremely rare in pediatric populations.\n* Locally advanced disease that is not amenable to surgical resection. Locally advanced PDAC cases will be identified per the definition developed by the Alliance for Clinical Trials in Oncology\\[53\\]. Per this definition, locally advanced PDAC is defined as presence of any one or more of the following on CT:\n\n  * Occlusion of the superior mesenteric vein (SMV) and\u002For portal vein (PV) that is not amenable to resection and venous reconstruction\n  * Interface between tumor and hepatic artery that is not amenable to resection and reconstruction\n  * Interface between the tumor and superior mesenteric artery (SMA) measuring \\> 180º of the circumference of the vessel wall\n  * Interface between the tumor and celiac axis measuring \\> 180º of the circumference of the vessel wall that is not amenable to resection\n* ECOG Performance Status of 0-2\n* Have adequate organ function per criteria below:\n\n  * Absolute neutrophil count (ANC) ≥ 1.5x109\u002FL\n  * Platelets ≥ 100x109\u002FL\n  * Hemoglobin ≥9 g\u002FdL\n  * Serum creatinine ≤1.5 x ULN OR creatinine clearance ≥40 mL\u002Fmin (as calculated by Modified Cockcroft-Gault formula)\n  * Serum total bilirubin ≤ 1.5 X ULN\n  * AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN\n* A minimum of 4 months of one of the chemotherapy regimens preferred by the NCCN for good performance status patients (currently modified FOLFIRINOX, gemcitabine + albumin-bound paclitaxel, or NALIRIFOX)\n* High quality imaging triphasic CT scan contrast-enhanced dynamic MRI of abdomen and either contrast-enhanced or non-contrast CT of chest and pelvis that demonstrate no evidence of metastatic disease within 30 days of enrollment\n* FDG-PET imaging (skullbase-midthigh) at any timepoint between diagnosis and study intervention to determine whether tumor is PET-avid and evaluate for extra-pancreatic metastatic disease, as suggested by NCCN guidelines for high-risk patients.\n* Tumor amenable to \"in situ\" (complete) ablation with maximum primary tumor dimension \\\u003C 4.0 cm\n* For participants able to become pregnant: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method until the study intervention and for an additional 1 month after the study intervention.\n* For participants able to cause a pregnancy: use of condoms or other methods to ensure effective contraception with partner for 1 month after study intervention.\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Known allergic reactions to components of the mitazalimab solution (L-Histidine, trehalose, or polysorbate 20)\n* Fever \\> 38 degrees C within 14 days of study intervention\n* Treatment with another investigational drug or other intervention within 30 days of enrollment\n* Prior treatment with a CD40 antibody\n* History of severe auto-immune disease\n* The presence of metal fiducials or embolization coils within the tumor.\n* Prior receipt of radiation therapy to the pancreas\n* The presence of implanted metallic cardiac stimulation devices within the chest\n* Uncontrolled cardiac arrhythmias that prevent synchronization of pulse delivery with the refractory period of the cardiac cycle\n* Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed topical corticosteroids (doses \\> 10 mg\u002Fday prednisone or equivalent) must be discontinued at least 2 weeks (14 days) before study treatment administration. Physiologic doses of corticosteroids (≤ 10 mg\u002Fday of prednisone or its equivalent) or short pulses of corticosteroids (≤ 3 days) may be permitted.\n* Any medical condition that precludes major abdominal surgery under general anesthesia\n* Presence of distant metastatic disease (including positive peritoneal cytology) on staging laparoscopy and\u002For exploratory laparotomy at any timepoint.",{"count":84,"type":20},[95],"This is a phase I study of an agonistic CD40 antibody (mitazalimab) injected intratumorally at the time of surgical IRE in patients with locally advanced pancreatic cancer. Intratumoral delivery has potential to be more effective than systemic (intravenous) delivery while decreasing the systemic side effects of immunotherapy. We hypothesize that local delivery of mitazalimab at the time of IRE in patients with locally advanced pancreatic cancer will be safe, augment the immune effects of IRE, and decrease the risk of recurrence.",[24],[472,473,474,475,476],"Irreversible electroporation (IRE)","NanoKnife","immunotherapy","CD40","Locally advanced pancreatic cancer",{"date":271,"type":36},{"date":479,"type":36},"2024-07-17",{"date":481,"type":20},"2030-08",{"name":483,"class":43},"University of California, San Diego",{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":492,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":502},"100490237","a-pan-european-post-authorisation-safety-study-risk-of-pancreatic-cancer-among-type-2-diabetes-patients-who-initiated-exenatide-as-compared-with-those-who-initiated-other-non-glucagon-like-peptide-1-receptor-agonists-based-glucose-lowering-drugs-100490237","NCT05663515","A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","EXCEED","For inclusion in either exposure group, all of the following inclusion criteria must be fulfilled:\n\n1. Aged 18 years or older at the index date\n2. Individual level data on prescriptions, diagnoses and medical history is available for a minimum of 12 months prior to the index date\n3. A diagnosis of T2DM on index date or prior to index date\n\nFor inclusion in the overall exenatide exposure group, the following criterion must be fulfilled:\n\n1. One incident prescription (or incident dispensed prescription) for exenatide (BYETTA or BYDUREON\u002F BYDUREON BCise) between the start and 12 months before the end of the study period. This incident prescription must have succeeded a prescription of a GLD of another drug class during the baseline period.\n\n   For inclusion in the BYDUREON\u002F BYDUREON BCise exposure group, for the analyses of the secondary objective, the criterion a) is substituted with criterion b):\n2. One incident prescription (or incident dispensed prescription) for BYDUREON\u002F BYDUREON BCise between the start and 12 months before the end of the study period. This incident prescription must have succeeded a prescription of a GLD of another drug class during the baseline period.\n\n   For inclusion in the comparator group, the following criterion must be fulfilled:\n3. One incident prescription (or incident dispensed prescription) of a GLD between the start and 12 months before the end of the study period. The GLD must not be a DPP-4i, a GLP-1 RA, or a combination with either a DPP-4i or a GLP-1 RA. This incident prescription must have succeeded a prescription of a GLD of another drug class during the baseline period.\n\nPatients are not eligible for any of the study population groups if they fulfil any of the following exclusion criteria:\n\n1. A diagnosis of type 1 diabetes mellitus (T1DM) on index date or a diagnosis of T1DM during the baseline period that is not succeeded by a T2DM diagnosis during the remaining part of the baseline period.\n2. A diagnosis of gestational diabetes during the baseline period or on index date.\n3. A diagnosis of polycystic ovarian syndrome during the baseline period or on index date in combination with exposure to metformin (Anatomical Therapeutic Chemical Classification System (ATC) code of the World Health Organization (WHO): A10BA02) as the only GLD on index date or during the baseline period.\n4. History of any cancer on or prior to index date. The only exception is that nonmelanoma skin cancer does not lead to exclusion.\n5. History of any acute pancreatitis, other diseases of the pancreas, or disorders of the pancreas on or prior to index date.\n6. One or more prescriptions (or dispensed prescriptions) of a GLP-1 RA (incretin mimetics) other than exenatide on or prior to index date.\n7. One or more prescriptions (or dispensed prescriptions) of DPP-4i (incretin mimetics) on or prior to the index date.",{"count":493,"type":20},24000,"EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other non-glucagon like peptide 1 receptor agonists (GLP-1 RA) based glucose lowering drugs (GLDs). Study data will be collected from secondary data sources across 7 European countries. The study will be conducted as a multi-country, long-term, retrospective, observational database study. Initiators of exenatide will be matched to initiators of non-GLP-1 RA based GLDs (comparator group) based on propensity score and calendar period of study entry. All analyses for pancreatic cancer will be conducted in the matched study population using an \"intention-to-treat\" approach. The study will use information from 8 data sources in 7 European countries (France, Spain, The United Kingdom, Finland, Denmark, Norway, and Sweden). Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide or non-GLP-1 RA based GLDs during the study period, 2006 to 2023, will be included. Exposure to exenatide and non-GLP-1 RA based GLDs will be ascertained from recordings of prescriptions or insurance claims registrations as available in the different data sources. The outcome of pancreatic cancer will be defined as a primary diagnosis of pancreatic cancer during follow-up.",[24],{"date":427,"type":36},{"date":498,"type":36},"2024-09-30",{"date":500,"type":20},"2026-10-01",{"name":227,"class":111},8,{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":54,"phases":512,"briefSummary":513,"conditions":514,"keywords":517,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":534},"100414594","phase-1-a-trial-of-rsc-1255-for-treatment-of-patients-with-advanced-malignancies-100414594","NCT04678648","A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies","A Phase Ia\u002FIb, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies","Inclusion Criteria (Key Factors):\n\n1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:\n\n   * Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition\n   * Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit\n   * Malignancy has progressed on standard therapy\n2. Has evaluable or measurable tumor(s) in dose-escalation by standard radiological and\u002For laboratory assessments as applicable to their malignancy.\n3. Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG).\n4. Is age ≥ 18 years.\n5. Has either tissue agnostic tumors and documented RAS mutations or with glioblastoma with or without mutation in RAS\n\nExclusion Criteria (Key Factors):\n\n1. Participants receiving cancer therapy at the time of enrollment.\n2. Any clinically significant disease or condition affecting a major organ system.\n3. Significant cardiovascular disease or electrocardiogram (ECG) abnormalities.\n4. Known Gilbert's disease.\n5. Has had a previous (within 2 years) or has a current malignancy other than the target cancer.\n6. Intermittent hypokalemia\n7. Grade 1 or higher nausea, vomiting, diarrhea at baseline due to underlying disease",{"count":511,"type":20},134,[95],"RSC-101 is a Phase 1a\u002F1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.",[515,367,71,64,516,24],"Advanced Malignant Solid Neoplasm","Glioblastoma",[518,519,520,521,522,523,516,524,525,526],"Malignancy","Cancer","Refractory","RAS mutation","Lung","Colon","RSC-1255","Progression","Pancreatic",{"date":427,"type":36},{"date":529,"type":36},"2021-03-03",{"date":531,"type":20},"2027-01-30",{"name":533,"class":111},"RasCal Therapeutics, Inc.",3,{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":542,"enrollmentInfo":543,"targetDuration":4,"studyType":54,"phases":545,"briefSummary":546,"conditions":547,"keywords":549,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":560},"100574136","alpha-radiation-emitters-device-dart-for-the-treatment-of-locally-advanced-pancreatic-cancer-100574136","NCT06755359","Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer","A Safety Study of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Histologically and\u002For cytologically proven locally advanced pancreatic adenocarcinoma\n* Target lesion is technically amenable for Alpha DaRT sources implantation.\n* Measurable lesion per RECIST (version 1.1) criteria\n* Stable disease or tumor response per RECIST (version 1.1) criteria compared to before initiation of mFOLFIRINOX\n* Lesion size ≤ 5 cm in the longest diameter\n* Interstitial radiation indication validated by a multidisciplinary team which includes an oncologist, a radiation oncologist, radiologist, gastroenterologist and a surgeon specialized in pancreatic oncology in the case that a surgical emergency occurs during the procedure\n* Patients have received 8 - 12 cycles of mFOLFIRINOX\n* ECOG Performance Status Scale 0 - 1\n* Life expectancy is more than 6 months\n* WBC ≥ 3500\u002Fµl, granulocyte ≥ 1500\u002Fµl\n* Platelet count ≥60,000\u002Fµl\n* Creatinine ≤1.9 mg\u002FdL\n* AST and ALT ≤ 2.5 X upper limit of normal (ULN)\n* INR \\\u003C 1.4 for patients not on Warfarin\n* Age ≥18 years old\n* Subjects are willing and able to sign an informed consent form\n* Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after initiation of Alpha DaRT therapy\n* Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after DaRT insertion.\n\nExclusion Criteria:\n\n* Concomitant immunotherapy within the past 4 weeks.\n* Patients with metastatic disease\n* Borderline unresectable pancreatic cancer, and\u002For cases fit for surgical exploration unless patient refuses surgery.\n* Known hypersensitivity to any of the components of the treatment.\n* Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids.\n* Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.\n* Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints.\n* Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, low risk prostate cancer, or in situ cervical cancer.\n* Patient requires treatment not specified in this protocol which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT.\n* Patients do not agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.\n* Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.\n* High probability of protocol non-compliance (in opinion of investigator).\n* Breastfeeding women or women of childbearing potential unwilling or unable to use an acceptable contraceptive method to prevent pregnancy for 3 months after RT.","120 Years",{"count":544,"type":20},40,[56],"A unique approach for cancer treatment including radioactive sources named Alpha DaRT sources: Ra - 224 coated onto stainless steel tubes inserted into the tumor for the treatment of Locally Advanced Pancreatic Cancer .",[24,548],"Locally Advanced Pancreatic Cancer",[550,551],"Alpha radiation","pancreatic cancer","2026-06-21",{"date":368,"type":36},{"date":555,"type":36},"2026-03-01",{"date":557,"type":20},"2027-06",{"name":559,"class":111},"Alpha Tau Medical LTD.",12,{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":570,"conditions":571,"keywords":573,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":4},"100643924","study-of-occupational-risk-factors-for-biliary-and-pancreatic-cancers-100643924","NCT07668024","Study of Occupational Risk Factors for Biliary and Pancreatic Cancers","PANTOXBIL","Inclusion Criteria:\n\n* Cases :\n\n  * Patients included in the TEDOPAM or IMMUNOBIL trials\n  * Diagnosis of biliary tract or pancreatic cancer\n  * Completed and exploitable curriculum laboris\n* Controls :\n\n  * Subjects from the CHOPPI cohort\n  * Age ≥ 18 years\n  * No biliary tract or pancreatic cancer\n  * No known familial predisposition to biliary tract or pancreatic cancers\n  * No opposition to data reuse\n\nExclusion Criteria:\n\n* Incomplete or non-exploitable occupational history\n* Refusal of data reuse",{"count":569,"type":20},210,"PANTOXBIL is a research project developed in the context of the increasing incidence of biliary tract and pancreatic cancers in France. Despite recent therapeutic advances, the prognosis of these cancers remains poor. Known risk factors do not fully explain the increase in incidence observed over recent decades. This suggests the possible role of emerging occupational and environmental risk factors, as reported in several epidemiological studies.\n\nThe PANTOXBIL study is based on the analysis of detailed curriculum laboris data (employment periods, occupations, tasks performed, and occupational exposures) collected during two multicenter phase II clinical trials, TEDOPAM and IMMUNOBIL, conducted between 2018 and 2021 in patients with pancreatic and biliary tract cancers.\n\nAn occupational exposure assessment was performed to calculate semi-quantitative cumulative exposure indices for each exposure or group of exposures for every participant. These indices will be compared with those of healthy controls from the CHOPPI cohort, initially designed to study occupational risk factors in COPD.\n\nPANTOXBIL is a matched case-control study based on sex, age, and smoking status. The aim is to compare cumulative occupational exposure indices between cases and controls in order to generate new hypotheses regarding occupational risk factors for biliary tract and pancreatic cancers.",[572,24],"Biliary Tract Cancer",[574,575,576,577,578],"Biliopancreatic cancers","Occupational exposure","Cumulative exposure index","Curriculum laboris","Case-control study","2026-06-19",{"date":271,"type":36},{"date":582,"type":20},"2026-08",{"date":584,"type":20},"2026-09",{"name":586,"class":43},"Centre Hospitalier Intercommunal Creteil",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":54,"phases":596,"briefSummary":597,"conditions":598,"keywords":600,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":605,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":44},"100641907","determining-minimal-residual-disease-using-ctdna-deep-sequencing-100641907","NCT07660627","Determining Minimal Residual Disease Using ctDNA Deep Sequencing","Determination of Minimal Residual Disease by Deep ctDNA Sequencing.","CIT-SEQ","Inclusion Criteria:\n\n* Consent to participate in the study\n* Patients with esophageal, gastric, or pancreatic cancer, stage 0-2\n* Patients with locally advanced, potentially operable disease treated with systemic perioperative chemotherapy or chemoradiotherapy\n* Patients with metastatic disease treated with first- to third-line palliative systemic therapy\n\nExclusion Criteria:\n\n* not specified",{"count":404,"type":20},[56],"Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse\u002Fprogression of disease.",[599,68,24],"Esophageal Adenocarcinoma",[601,602,603,604],"Minimal residual disease","NGS sequencing","gastrointestinal tumors","Preoperative neoadjuvant chemotherapy",{"date":368,"type":36},{"date":607,"type":36},"2022-08-22",{"date":609,"type":20},"2026-12-31",{"name":611,"class":43},"Masaryk Memorial Cancer Institute",{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":54,"phases":620,"briefSummary":621,"conditions":622,"keywords":624,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":633,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":640},"100622718","mainstreaming-genetics-evaluation-of-a-digital-application-to-scale-and-spread-oncologist-initiated-genetic-testing-100622718","NCT07387263","Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing","Inclusion Criteria:\n\n* Receiving germline testing related to primary cancer condition initiated by oncologist\n* 18 years old or older.\n* Speak and read English\n\nExclusion Criteria:\n\n* Receiving cancer genetic testing via a referral to a genetics clinic\n* Do not speak or read English\n* Under 18 years of age\n* Determined to have diminished, marginal and or fluctuating decisional capacity\n* Lack access to internet or an electronic device",{"count":619,"type":20},180,[56],"Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon\u002FGI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a standardized, coordinated and patient-centered approach to deliver cancer genetic education. However, digital solutions for providing cancer genetics services are uncommon and clinical-effectiveness and service delivery outcomes have not been well-assessed. This study will test a digital mainstreaming platform called the Genetics Adviser for Mainstream care to assess its effectiveness in improving psychological outcomes and patient-centred care for mainstream cancer patients compared to standard of care.",[519,62,74,64,623,73,24],"GI Cancers",[625,626,627,628,629,519,630,631,632],"Cancer Genetic Testing","Randomized Controlled Trial","Digital Tool","Mainstreaming","Genetic counseling","Genetic testing","Service Delivery","Alternative service delivery model",{"date":368,"type":36},{"date":635,"type":36},"2026-04-30",{"date":637,"type":20},"2027-03",{"name":639,"class":43},"Unity Health Toronto",2,{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":648,"targetDuration":4,"studyType":54,"phases":650,"briefSummary":651,"conditions":652,"keywords":663,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":679,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":686},"100614270","phase-1-a-study-of-ide892-as-monotherapy-and-combination-in-mtap-deleted-advanced-solid-tumors-100614270","NCT07277413","A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors","A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors","Inclusion Criteria:\n\n* Are ≥ 18 years of age (or the minimum age of consent in accordance with local regulations) at the time of signing the ICF.\n* Have a histologically confirmed diagnosis of a locally advanced recurrent or metastatic solid tumor type of interest with MTAP deletion (for dose escalation: mesothelioma \\[pleural or peritoneal\\], gastroesophageal cancers \\[squamous and adenocarcinoma of esophagus, gastric adenocarcinoma, gastroesophageal junction cancers\\], pancreatic adenocarcinoma and biliary tract carcinomas (intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder cancer), NSCLC \\[adenocarcinoma, squamous cell carcinoma, and adeno-squamous\\] or UC \\[including mixed urothelial-squamous histology\\]; for dose expansion: NSCLC that has progressed on at least one prior line of treatment and for which additional effective standard therapy is not available or for which the participant is not a candidate due to intolerance).\n* Are willing and able to provide blood\u002Ftumor tissue samples for biomarker testing. An archival tumor tissue specimen must be provided for central confirmation of MTAP loss.\n* Must be willing and able to provide the blood\u002Fserum\u002Fplasma samples\n* Have evidence of homozygous loss of MTAP or MTAP deletion (pre-screening available after signing pre-screening ICF)\n* Have at least 1 measurable lesion according to RECIST version 1.1\n* Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1\n* Have life expectancy \\> 3 months\n* Have adequate bone marrow and organ function\n* Able to swallow and retain orally administered study drug\u002FIMP.\n* Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures\n* Male and female: willing to use contraception\n\nExclusion Criteria:\n\n* Known symptomatic brain metastases requiring supraphysiologic doses of systemic corticosteroids\n* Have a known primary central nervous system (CNS) malignancy\n* Have had other malignancies within 2 years prior to the first dose, with some exceptions\n* Impaired cardiac function or clinically significant cardiac diseases\n* Have presence of uncontrolled pleural, peritoneal, or pericardial effusion within 2 weeks before the first study dose, requiring recurrent drainage procedures or an indwelling drainage catheter\n* Have a history of severe infections within 4 weeks prior to the start of study treatment\n* Hypertension (e.g., \\> 150\u002F100 mmHg) that cannot be controlled by medications despite optimal medical therapy\n* Other acute or chronic medical or psychiatric condition\n* Have a history of immunodeficiency, with a positive human immunodeficiency virus(HIV) test at screening\n* Known or suspected viral hepatitis with a positive test at screening\n* Had an adverse reaction to a previous antitumor treatment that has not recovered to CTCAE Grade ≤ 1\n* Have received chemotherapy within 4 weeks of the first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 2 weeks before the first dose of IMP; small molecule inhibitors within 2 weeks before the first dose of IMP, or other investigational products within 4 weeks\n* Current radiation-related toxicity or radiation therapy within 2 weeks before the first dose of IMP\n* Administration of any of the following within 2 weeks before the first dose of IDE892 as a monotherapy: Strong inhibitors or inducers of cytochrome P450, Strong inhibitors of P-glycoprotein, Narrow therapeutic index and sensitive substrates of multidrug and toxin extrusion (MATE)1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and breast cancer resistance protein\n* Administration of any of the following within 2 weeks before the first dose of IDE892: Strong inhibitors or inducers of CYP3A4\u002F5, Strong inhibitors of P-gp and\u002For BCRP, Narrow therapeutic index and sensitive substrates of MATE1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and BCRP\n* Use of proton pump inhibitors (PPIs) within 7 days prior to the first dose of IMP or planned use during the study\n* Use of drugs with known risk for QT prolongation within 2 weeks prior to the first dose of IDE892\n* Previous treatment with a Amethionine adenosyltransferase 2A (MAT2A) inhibitor and\u002For Protein arginine N-methyltransferase (PRMT) inhibitor\n* Major surgery within 4 weeks before study entry\n* Prior irradiation to \\> 25% of the bone marrow\n* Known or suspected hypersensitivity to IDE892\n\nDisease-Specific Eligibility Criteria Eligibility Criteria for Participants with NSCLC (All Parts)\n\n* Must have histologically confirmed diagnosis of advanced or metastatic NSCLC that has progressed after prior treatment with platinum chemotherapy and a PD-1\u002FPD-L1 inhibitor (unless contraindicated or participant developed intolerance) in the metastatic setting\n* Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease.\n* If considered standard of care and available, participants whose cancers have proven targetable oncogene alterations must have had disease progression on (unless contraindicated or participant developed intolerance) at least 1 prior line containing appropriate targeted therapy.\n\nEligibility Criteria for Participants with Urothelial Cancer (Bladder and Upper Urinary Tract), Mesothelioma (Pleural or Peritoneal), Pancreatic Adenocarcinoma or Biliary Tract Carcinomas (Intrahepatic and Extrahepatic Cholangiocarcinoma, and Gallbladder Cancer) (Parts 1 and 3)\n\n* Must have histologically confirmed diagnosis of advanced or metastatic UC, mesothelioma, gastroesophageal cancer or pancreatic and biliary tract tumors\n* Must have progressed following at least 1 prior line of therapy\n* Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease",{"count":649,"type":20},260,[95],"This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.",[653,654,655,656,657,658,206,315,659,660,661,24,662],"NSCLC Adenocarcinoma","Gastroesophageal Cancer (GC)","Gastric Adenocarcinoma","Adenocarcinoma of Esophagus","Squamous Cell Car. - Esophagus","Urothelial Carcinoma (UC)","Pleural Mesothelioma","Peritoneal Mesothelioma","Non-Small Cell Lung Cancer NSCLC","Biliary Tract Carcinoma",[664,665,666,667,668,669,670,671,672,673,674,675,676,677,678],"MTAP deletion","MTAP loss","MTAP-deficient tumors","homozygous MTAP loss","IDE892","IDE397","MAT2A inhibitor","PRMT5","advanced solid tumors","metastatic cancer","recurrent cancer","dose escalation","dose expansion","phase 1 clinical trial","ctDNA",{"date":427,"type":36},{"date":681,"type":36},"2026-03-04",{"date":683,"type":20},"2028-04-30",{"name":685,"class":111},"IDEAYA Biosciences",14,{"id":688,"slug":689,"hasResults":12,"nctId":690,"briefTitle":691,"officialTitle":692,"acronym":4,"eligibilityCriteria":693,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":694,"targetDuration":4,"studyType":54,"phases":696,"briefSummary":697,"conditions":698,"keywords":705,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":720,"startDateStruct":721,"completionDateStruct":723,"leadSponsor":725,"locationsCount":435},"100439677","phase-1-study-to-assess-adverse-events-and-pharmacokinetics-in-adult-participants-with-non-small-cell-lung-cancer-head-and-neck-squamous-cell-carcinoma-and-other-solid-tumors-receiving-intravenous-infusion-of-azirkitug-alone-or-in-combinations-with-budigalimab-bevacizumab-or-telisotuzumab-adizutecan-100439677","NCT05005403","Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan","A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors With Azirkitug as a Single Agent and in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan","Inclusion Criteria:\n\n* Pre Treatment biopsy or archive tissue within 6 months without intervening treatment\n* Eastern Cooperative Oncology Group (ECOG) performance status of \\\u003C= 0 or 1 and a life expectancy of \\>= 3 months.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)\n* Laboratory values meeting criteria outlined in the protocol\n* NSCLC - Advanced or metastatic progressed on standard of care (SOC) including chemotherapy and prior anti-PD-(L)1 antibody (separately or in combination). Actionable gene alterations are eligible if failed targeted therapeutic options.\n* HSNCC - Advanced\u002Fmetastatic progressed on platinum and PD-1\u002FPD-LI in recurrent or metastatic setting.\n* Micro Satellite Stable Colorectal Cancer (MSS-CRC) - Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, BRAFV600E or HER2, other targetable mutations targeted with locally approved therapy, TAS-102, Regorafenib and not MSI-h or MMR-deficient\n* Gastric and Gastroesophageal Junction adenocarcinoma (GEA) - Advanced\u002Fmetastatic progressed on at least 1 prior cytotoxic chemotherapeutic regimen and if applicable immune checkpoint inhibitor and\u002For HER2 therapy\n* High-Grade Serous Ovarian Cancer (HGSOC) - Progressed serous epithelial ovarian, fallopian tube or primary peritoneal cancer post SOC and not eligible for surgical resection. Platinum resistant cannot have \\>5 lines of prior therapy.\n* Pancreatic Adenocarcinoma (PDAC) - Advanced\u002Fmetastatic progressed after SOC. Includes adenosquamous carcinoma and post-Whipple.\n* Triple Negative Breast Cancer (TNBC) - Progressed after 1 or 2 systemic therapy that must have included taxane and treatment naïve to immunotherapy targeting T-cell co-stimulation\n\nExclusion Criteria:\n\n* Pancreatic Ductal Adenocarcinoma (PDAC) - Excludes neuroendocrine or acinar pancreatic carcinoma and participants with coagulopathy or at risk of or history of Deep vein thrombosis (DVT)\u002FPE\n* No major surgery within 28 days prior to dosing\n* No active autoimmune\u002Fimmunodeficiency disease with limited exceptions\n* Combination treatment excludes participants treated with anti-programmed cell death protein 1(PD-1)\u002FProgrammed cell death ligand 1 (PD-L1) who had immune mediated toxicity G3 or greater, interstitial lung disease, or hypersensitivity Combination treatment may also require no significant cardiac deficiencies and\u002For events\n* Pregnancy\n* Excluded medications include anticancer therapy within 5 half-live or 28 days (whichever is shorter), agent targeting Chemokine Receptor (CCR)8, live vaccines, immunosuppressive medication with limited exceptions",{"count":695,"type":20},694,[95],"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck. The purpose of this study is to assess adverse events and pharmacokinetics of azirkitug as a monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan.\n\nBevacizumab is an approved product, while budigalimab, azirkitug, and telisotuzumab adizutecan are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)\u002Fmaximum administered dose (MAD) of azirkitug will be explored. Each treatment arm receives a different dose of azirkitug in monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Approximately 694 adult participants will be enrolled in the study across approximately 80 sites worldwide.\n\nParticipants will receive azirkitug as a monotherapy or in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan as an Intravenous (IV) Infusion for an estimated treatment period of up to 2 years.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[699,700,701,702,703,24,704],"Non-Small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Micro Satellite Stable Colorectal Cancer","Gastric\u002FEsophageal Cancer","High-Grade Serous Ovarian Cancer","Triple Negative Breast Cancer",[699,706,700,707,708,709,710,711,701,712,66,713,714,703,715,716,704,717,718,719],"NSCLC","HNSCC","Solid Tumors","Budigalimab","ABBV-181","ABBV-514","MSS-CRC, Gastric Cancer","GEA","GEJ","HGSOC","Pancreatic Cancer, PDAC","TNBC","Telisotuzumab Adizutecan","ABBV-400",{"date":427,"type":36},{"date":722,"type":36},"2021-11-01",{"date":724,"type":20},"2027-07",{"name":726,"class":111},"AbbVie",{"id":728,"slug":729,"hasResults":12,"nctId":730,"briefTitle":731,"officialTitle":732,"acronym":733,"eligibilityCriteria":734,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":735,"targetDuration":4,"studyType":54,"phases":737,"briefSummary":738,"conditions":739,"keywords":740,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":748,"lastUpdatePostDateStruct":749,"startDateStruct":750,"completionDateStruct":752,"leadSponsor":754,"locationsCount":756},"100636166","phase-3-atebimetinib--gnp-as-a-first-line-treatment-in-patients-with-metastatic-pancreatic-adenocarcinoma-100636166","NCT07562152","Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)","MAPKeeper 301","Inclusion Criteria:\n\n* Must be ≥18 years of age\n* Must have confirmed diagnosis according to AJCC staging as follows:\n\n  * Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participants must be treatment naive as follows:\n\n  * First-line PDAC participants will have received no previous systemic anti-cancer therapy\n* Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria\n* Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values\n\nExclusion Criteria:\n\n* Inability to swallow oral medications\n* Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma\n* Participants with only locally advanced disease\n* Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases",{"count":736,"type":20},510,[351],"The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.",[24,354,355,356,361,357,247,358],[741,742,743,673,744,745,746,747],"mitogen-activated protein kinase (MAPK)","MAPK","MEK","gemcitabine","nab-paclitaxel","nab-p","atebimetinib","2026-06-18",{"date":452,"type":36},{"date":751,"type":20},"2026-06",{"date":753,"type":20},"2029-02",{"name":755,"class":111},"Immuneering Corporation",19,{"id":758,"slug":759,"hasResults":12,"nctId":760,"briefTitle":761,"officialTitle":762,"acronym":763,"eligibilityCriteria":764,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":765,"targetDuration":4,"studyType":54,"phases":767,"briefSummary":768,"conditions":769,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":748,"lastUpdatePostDateStruct":770,"startDateStruct":771,"completionDateStruct":773,"leadSponsor":775,"locationsCount":777},"100577715","topanc-trial-survival-after-total-versus-partial-pancreaticoduodenectomy-for-adenocarcinoma-of-the-pancreatic-head-distal-cholangiocarcinoma-and-ampullary-cancer-100577715","NCT06801899","ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer","ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer: a Multi-centric Randomized Controlled Trial","ToPanc","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years) scheduled to undergo PD for highly suspected or histologically proven, resectable pancreatic ductal adenocarcinoma (PDAC), distal cholangiocarcinoma (DCC), and\u002For ampullary cancer (pancreaticobiliary type)\n* Suspected pancreas anastomosis at high-risk for development of a postoperative pancreatic fistula (POPF) (grade \"D\" according to Schuh et al. (29): Estimation by CT scan, MRI, and\u002For Endoscopic Ultrasound\n* Written informed consent\n\nExclusion Criteria:\n\n* Duodenal carcinoma, ampullary cancer (intestinal type), neuroendocrine tumors, benign tumors, chronic pancreatitis\n* Medical conditions that do not allow appreciation of the nature, scope, and possible consequences of the trial as judged by the investigator\n* Pregnancy. A beta-Human Chorionic Gonadotropin (bHCG) pregnancy test must to be performed for women of child-bearing potential (defined as premenopausal women who have not undergone surgical sterilization)\n* Inability to follow the study procedures, e.g., due to psychological disorders, dementia, etc.",{"count":766,"type":20},170,[56],"The goal of this clinical trial is to learn if total removal of the pancreas is a preferable alternative to partial removal in patients with cancer of the pancreatic head who are at high risk of pancreatic leakage. The main question it aims to answer is:\n\nDoes total pancreas removal improve survival without reducing quality of life compared to partial removal?\n\nThe only study specific procedures are the collection of 2 blood samples (7.5ml for each time point, preoperatively and during the hospitalisation) and the completion of the questionnaires.",[24],{"date":427,"type":36},{"date":772,"type":36},"2026-06-01",{"date":774,"type":20},"2030-10",{"name":776,"class":43},"Insel Gruppe AG, University Hospital Bern",10]